dostarlimab (Jemperli)

following a full submission assessed under the end of life and orphan equivalent medicine process:

dostarlimab (Jemperli®) is not recommended for use within NHSScotland.

Indication under review: in combination with platinum-containing chemotherapy for the treatment of adult patients with primary advanced or recurrent endometrial cancer and who are candidates for systemic therapy.

In a phase III study, dostarlimab compared with placebo, numerically improved progression-free survival in adults with primary advanced or first recurrence of endometrial cancer who had proficient mismatch repair (pMMR)/microsatellite stable (MSS) disease.

The submitting company’s justification of the treatment’s cost in relation to its health benefits was not sufficient and in addition the company did not present a sufficiently robust economic analysis to gain acceptance by SMC.

This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.

SMC has previously accepted dostarlimab for use in combination with platinum-containing chemotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer and who are candidates for systemic therapy (SMC2635). This advice remains valid.

The submitting company has indicated their intention to make a resubmission.